Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
10-01-03 Drugs affecting the immune response
| Azathioprine |
|
Formulary
|
Tablets 25mg, 50mg |
 LSCMMG: Azathioprine and Mercaptopurine shared care guideline MHRA: Thiopurines and intrahepatic cholestasis of pregnancy |
|
| Ciclosporin |
|
Formulary
|
Capsules 25mg, 50mg, 100mg Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration. |
|
LSCMMG: Ciclosporin shared care guideline |
|
|
| Cyclophosphamide |
|
Formulary
|
Tablets 50mg |
|
| Leflunomide |
|
Formulary
|
Tablets 10mg, 20mg |
|
LSCMMG: Leflunomide shared care guideline |
|
|
| Methotrexate |
|
Formulary
|
Tablets 2.5mg Prefilled syringes and pens (various strengths) Methotrexate subcutaneous injection may be supplied through a homecare arrangement. |
|
LSCMMG: Methotrexate shared care guideline MHRA: Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing MHRA: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions |
|
|
| Mycophenolate Mofetil |
|
Formulary
|
Tablets 500mg |
|
LSCMMG: Shared care guideline: Mycophenolate Mofetil MHRA: Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men MHRA: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients |
|
| Sulfasalazine |
|
Formulary
|
Tablets 500mg Gastro-resistant tablets 500mg Sulfasalazine has been confused with sulfadiazine; care must be taken to ensure the correct drug is prescribed and dispensed. |
|
LSCMMG: Sulfasalazine shared care guideline |
|
|
Links
- Baricitinib (Olumiant▼): risk of venous thromboembolism
- LSCMMG Shared Care Guideline - Azathioprine and mercaptopurine
- LSCMMG Shared Care Guideline - ciclosporin
- LSCMMG Shared Care Guideline - Leflunomide
- LSCMMG Shared Care Guideline - Methotrexate
- LSCMMG Shared Care Guideline - Methotrexate
- LSCMMG Shared Care Guideline - Methotrexate
- LSCMMG Shared care guideline - penicillamine
- LSCMMG Shared Care Guideline - sodium aurothiomalate (gold) injection
- LSCMMG Shared Care Guideline - Sulfasalazine
- LSCMMG: Azathioprine and Mercaptopurine shared care guideline
- LSCMMG: Ciclosporin shared care guideline
- LSCMMG: Hydroxychloroquine information sheet
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Juvenile Idiopathic Arthritis in adult patients: Position statement for biological agents
- LSCMMG: Leflunomide shared care guideline
- LSCMMG: Methotrexate shared care guideline
- LSCMMG: Penicillamine shared care guideline
- LSCMMG: Primary Care Constipation Guidelines
- LSCMMG: Shared care guideline: Mycophenolate Mofetil
- LSCMMG: Sulfasalazine shared care guideline
- MHRA advice regarding risk of hepatotoxicity, haemotoxicity, infections, and birth defects
- MHRA Drug Safety Update Aug 2020: Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors
- MHRA Drug Safety Update July 2019: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- MHRA Drug Safety Update Mar 2020: Tofacitinib (Xeljanz): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
- MHRA Drug safety Update March 2020: Baricitinib (Olumiant): risk of venous thromboembolism
- MHRA Drug Safety Update may 2019: Tofacitinib (Xeljanz): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing
- MHRA Drug Safety Update Oct 2021: Tofacitinib (Xeljanz): new measures to minimise risk of major adverse cardiovascular events and malignancies
- MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Apremilast (Otezla ▼): risk of suicidal thoughts and behaviour
- MHRA: Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors
- MHRA: Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing
- MHRA: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions
- MHRA: Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men
- MHRA: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients
- MHRA: Rituximab: screen for hepatitis B virus before treatment
- MHRA: Thiopurines and intrahepatic cholestasis of pregnancy
- MHRA: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies
- MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
- MHRA: Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing
- MHRA: Tuberculosis riskscreen patients before starting treatment
- MHRA: Tuberculosis riskscreen patients before starting treatment
- MHRA: Tuberculosis riskscreen patients before starting treatment
- MHRA: Tuberculosis riskscreen patients before starting treatment
- MHRA: Tuberculosis riskscreen patients before starting treatment
- MHRA: Tumour necrosis factor alpha inhibitors
- MHRA: Tumour necrosis factor alpha inhibitors
- MHRA: Tumour necrosis factor alpha inhibitors
- MHRA: Tumour necrosis factor alpha inhibitors
- MHRA: Tumour necrosis factor alpha inhibitors
- MHRA: Ustekinumab (Stelara): risk of exfoliative dermatitis
- NHSE: Clinical commissioning policy: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older) [2319]
- NHSE: Clinical commissioning policy: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older) [2319]
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG191 COVID-19 rapid guideline: managing COVID-19
- NICE Q&A: Interaction between methotrexate and penicillins
- NICE TA 225: rheumatoid arthritis
- NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
- NICE TA143: Ankylosing spondylitis
- NICE TA143: Ankylosing spondylitis
- NICE TA143: Ankylosing spondylitis
- NICE TA167: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA195: After the failure of a TNF inhibitor
- NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
- NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
- NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- NICE TA199: Psoriatic arthritis
- NICE TA199: Psoriatic arthritis
- NICE TA199: Psoriatic arthritis
- NICE TA220: Golimumab for the treatment of psoriatic arthritis
- NICE TA220: psoriatic arthritis
- NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
- NICE TA233: ankylosing spondylitis
- NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
- NICE TA340: Ustekinumab for treating active psoriatic arthritis
- NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
- NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
- NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
- NICE TA433: Apremilast for treating active psoriatic arthritis
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
- NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
- NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis
- NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
- NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
- NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
- NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
- NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
- NICE TA518: Tocilizumab for treating giant cell arteritis
- NICE TA518: Tocilizumab for treating giant cell arteritis
- NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
- NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
- NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
- NICE TA596:Risankizumab for treating moderate to severe plaque psoriasis
- NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
- NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
- NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis
- NICE TA676; Filgotinib for treating moderate to severe rheumatoid arthritis
- NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
- NICE TA685: Anakinra for treating Stills disease
- NICE TA685:Anakinra for treating Stills disease
- NICE TA711: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA718: Ixekizumab for treating axial spondyloarthritis
- NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
- NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis
- NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis
- NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
- NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
- NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
- NICE TA814 : Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA829: Upadacitinib for treating active ankylosing spondylitis
- NICE TA829: Upadacitinib for treating active ankylosing spondylitis
- NICE TA829: Upadacitinib for treating active ankylosing spondylitis
- NICE TA861 Upadacitinib for treating active non-radiographic axial spondyloarthritis
- NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease
- NICE TA916: Bimekizumab for treating active psoriatic arthritis
- NICE TA916: Bimekizumab for treating active psoriatic arthritis
- NICE TA918: Bimekizumab for treating axial spondyloarthritis
- NICE TA918:Bimekizumab for treating axial spondyloarthritis
- NICE TA920: Tofacitinib for treating active ankolysing spondylitis
- NICE TA920: Tofacitinib for treating active ankylosing spondylitis
- NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)
- NICETA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- Policy for prescribing and supply of methotrexate to inpatients
- UKMI Q and A: Can mothers breast feed while taking azathioprine?
- UKMI Q&A: Methotrexate and alcohol guidance